Scientists Develop Test to Identify Best Treatment for Gonorrhea

Researchers from UCLA have developed a laboratory test that helps physicians determine which people with gonorrhea may be more treatable with an antibiotic that has not been recommended since 2007 because of concerns that the resistance to the drug was growing.

Gonorrhea has developed increasing resistance to all current antibiotics. Due to the spread of multidrug-resistant gonorrhea, health authorities have declared it one of the top-three urgent threats to public health.

Ciprofloxacin was used to combat the sexually transmitted infection until 2007, when the Centers for Disease Control and Prevention stopped recommending its use after gonococcal infections developed resistance to it. Nevertheless, about 80 percent of gonorrhea infections in the United States, however, could be treated with ciprofloxacin. Scientists have been trying to determine how to better identify cases for targeted use of ciprofloxacin therapy, reducing the need to use the antibiotic ceftriaxone and risking increased resistance to that drug. Gonorrhea's resistance rate to ceftriaxone is currently less than 1 percent.

The research was conducted at UCLA Health's hospitals, emergency departments and primary care clinics. After developing a test to detect a genetic change in gonorrhea that makes it resistant to ciprofloxacin, the researchers noted what treatments UCLA physicians had been using to treat gonorrhea. They then used the new test for all gonorrhea cases over a nine-month period and compared treatments before and after test introduction.

Based on the results from the new DNA test, physicians appropriately changed treatment choices decreasing the use of ceftriaxone from 100 percent of the time to 60 percent. Correspondingly, the use of ciprofloxacin increased from 0 percent to 40 percent of cases.

These findings are important because there are a limited number of medications to treat gonorrhea. Reusing previously effective antibiotics and decreasing the use of ceftriaxone may slow down the continued emergence of antibiotic resistance.

The authors of the study are Lao-Tzu Allan-Blitz, Romney Humphries, Peera Hemarajata, Ashima Bhatti, and Jeffrey Klausner of UCLA; Mark Pandori of the Alameda County Department of Public Health; and Mark Siedner of Harvard University.

The study was published in the May 1 issue of Clinical Infectious Diseases.

This work was supported by the David Geffen School of Medicine at UCLA and the National Institutes of Health (grant numbers R21AI117256 and R21AI109005).

Source: University of California - Los Angeles Health Sciences